Evaluation of Saudi Arabian Pharmacists' Awareness and Expertise about Ledipasvir Sofosbuvir

Introduction: Ledipasvir/sofosbuvir is a fixed-dose combination of two antiviral drugs with different mechanisms of action. It is used to treat chronic hepatitis C genotype 1 infection in adults as a fixed-dose combination tablet containing 90 mg ledipasvir and 400 mg sofosbuvir. Objective of the Study: To assess and evaluate the actual knowledge of pharmacists in Saudi Arabia about different aspects regarding ledipasvir sofosbuvir combination. Method: Cross sectional survey was conducted from November 2022 to November 2023. A total of 180 pharmacists participated in the study. The inclusion criteria are to be a licensed and currently practicing pharmacist or clinical pharmacist and exclusion criteria is being pharmacist technician or pharmacist aid. Data collection was carried out using a questionnaire, especially designed for this study. The questionnaire was divided into 2 parts. Data were analyzed using excel Categorical variables using frequency distribution and percentages. Results: In this study 34 % of pharmacists were community pharmacists while 50% were hospital pharmacists. Males accounted for 52% of pharmacists. Highest proportion (58%) of the participants were in the age group (25 to 30 years) and majority (72%) had one to five years of practice years. The average of good knowledge about indications, dosage and administration of ledipasvir-sofosbuvir equal 57%. The average of good knowledge about drug interactions of Ledipasvir-sofosbuvir equal 54%. The average of good knowledge about drug interactions of Ledipasvir-sofosbuvir equal 58%. The overall average of good knowledge (correct answers) of all pharmacists included in the study regarding ledipasvir-sofosbuvir equal 56%. Conclusion: As a conclusion, large proportion of the study sample lack adequate knowledge in certain important aspects of ledipasvir sofosbuvir which is an FDA approved interferon-free regimen for patients with chronic HCV. This might negatively affect the role of pharmacists in patient counseling and education.

Authors

Institutions

Publication Details

Journal
Journal of Pharmaceutical Research International
Published
2024-12-26
DOI
https://doi.org/10.9734/jpri/2024/v36i127638
Primary Topic
Hepatitis C virus research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Evaluation of Saudi Arabian Pharmacists' Awareness and Expertise about Ledipasvir Sofosbuvir

Shuaa Rakan Alrwilli
Journal of Pharmaceutical Research International
Hepatitis C virus research
article

Evaluation of Saudi Arabian Pharmacists' Awareness and Expertise about Ledipasvir Sofosbuvir

Shuaa Rakan Alrwilli
article en

Abstract

Introduction: Ledipasvir/sofosbuvir is a fixed-dose combination of two antiviral drugs with different mechanisms of action. It is used to treat chronic hepatitis C genotype 1 infection in adults as a fixed-dose combination tablet containing 90 mg ledipasvir and 400 mg sofosbuvir. Objective of the Study: To assess and evaluate the actual knowledge of pharmacists in Saudi Arabia about different aspects regarding ledipasvir sofosbuvir combination. Method: Cross sectional survey was conducted from November 2022 to November 2023. A total of 180 pharmacists participated in the study. The inclusion criteria are to be a licensed and currently practicing pharmacist or clinical pharmacist and exclusion criteria is being pharmacist technician or pharmacist aid. Data collection was carried out using a questionnaire, especially designed for this study. The questionnaire was divided into 2 parts. Data were analyzed using excel Categorical variables using frequency distribution and percentages. Results: In this study 34 % of pharmacists were community pharmacists while 50% were hospital pharmacists. Males accounted for 52% of pharmacists. Highest proportion (58%) of the participants were in the age group (25 to 30 years) and majority (72%) had one to five years of practice years. The average of good knowledge about indications, dosage and administration of ledipasvir-sofosbuvir equal 57%. The average of good knowledge about drug interactions of Ledipasvir-sofosbuvir equal 54%. The average of good knowledge about drug interactions of Ledipasvir-sofosbuvir equal 58%. The overall average of good knowledge (correct answers) of all pharmacists included in the study regarding ledipasvir-sofosbuvir equal 56%. Conclusion: As a conclusion, large proportion of the study sample lack adequate knowledge in certain important aspects of ledipasvir sofosbuvir which is an FDA approved interferon-free regimen for patients with chronic HCV. This might negatively affect the role of pharmacists in patient counseling and education.

Journal of Pharmaceutical Research InternationalVol. 36(12)
King Fahd Security College (SA)
Quality Education
Openalex Percentile: Top 62%
Hepatitis C virus research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.